1
|
Cardona L, San Martín J, Benito L, Tomás J, Abella E, Eymar J, Aguilera M, Esteban JA, Tarragó A, Marco A. Global warming facilitates the nesting of the loggerhead turtle on the Mediterranean coast of Spain. Anim Conserv 2022. [DOI: 10.1111/acv.12828] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- L. Cardona
- IRBio and Department of Evolutionary Biology, Ecology and Environmental Science, Faculty of Biology University of Barcelona Barcelona Spain
| | | | - L. Benito
- IRBio and Department of Evolutionary Biology, Ecology and Environmental Science, Faculty of Biology University of Barcelona Barcelona Spain
| | - J. Tomás
- Cavanilles Institute of Biodiversity and Evolutionary Biology University of Valencia Valencia Spain
| | - E. Abella
- BETA Technological Center, Universitat de Vic‐ Universitat Central de Catalunya Futurlab‐Can Baumann Vic Spain
| | - J. Eymar
- Conselleria de Agricultura, Desarrollo Rural, Emergencia Climática y Transición Ecológica Dirección General del Medio Natural, Servicio de Vida Silvestre Valencia Spain
| | - M. Aguilera
- BETA Technological Center, Universitat de Vic‐ Universitat Central de Catalunya Futurlab‐Can Baumann Vic Spain
| | | | - A. Tarragó
- Departament d'Acció Climàtica, Alimentació Agenda Rural Generalitat de Catalunya Barcelona Spain
| | - A. Marco
- Estación Biológica de Doñana CSIC Sevilla Spain
| |
Collapse
|
2
|
Martins S, Cardona L, Abella E, Silva E, Loureiro N, Roast M, Marco A. Effect of body size on the long-term reproductive output of East Atlantic loggerhead turtles Caretta caretta. ENDANGER SPECIES RES 2022. [DOI: 10.3354/esr01198] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
|
3
|
Marco A, Martins S, Martín-Rábano A, Lopes S, Clarke LJ, Abella E. Risk assessment of wildlife-watching tourism in an important endangered loggerhead turtle rookery. ENDANGER SPECIES RES 2021. [DOI: 10.3354/esr01130] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
Abstract
Wildlife-watching tourism is a non-exploitative activity that can contribute to sustainable economic development of coastal communities. However, it is important to assess the potential impact and implement best practices to mitigate any negative effects of such tourism. We studied this issue on Boa Vista (Cabo Verde), which supports around 60% of nesting activity of one of the most endangered loggerhead turtle rookeries globally. Between 2013 and 2016, authorized turtle watching involved 4942 tourists, generating a mean annual direct income of >USD 289000 and the direct creation of >250 jobs. On João Barrosa beach, which supports around 20% of nests and 48% of turtle-watching activity on the island, we tested the influence of turtle watching on nesting behavior, reproduction and nest-site fidelity. Nesting females observed by tourists spent significantly less time on nest-camouflaging behavior, although all other phases of nesting were unaffected. There were no statistically significant differences between the re-nesting frequency of females watched (n = 187) and non-watched (n = 972) by tourists. We found no evidence that the current turtle-watching intensity has an effect on turtle reproduction. Turtle poaching remains a severe threat on beaches with no turtle watching, although it has strongly decreased on beaches with tourist visits. We suggest tour guides follow best practice guidelines to minimize disturbance, specifically retreating from the immediate vicinity of a female during nest camouflaging to mitigate the observed impact.
Collapse
Affiliation(s)
- A Marco
- Estación Biológica de Doñana, CSIC, C/ Américo Vespucio s/n, Sevilla 41092, Spain
- BIOS.CV, C/ Sta Isabel s/n, Sal Rei, 5211 Boa Vista, Cabo Verde
| | - S Martins
- BIOS.CV, C/ Sta Isabel s/n, Sal Rei, 5211 Boa Vista, Cabo Verde
| | - A Martín-Rábano
- BIOS.CV, C/ Sta Isabel s/n, Sal Rei, 5211 Boa Vista, Cabo Verde
| | - S Lopes
- Direcção Geral do Ambiente, Cha d’ Areia s/n, Praia, 332A Santiago Island, Cabo Verde
| | - LJ Clarke
- School of Ocean Sciences, Bangor University, Menai Bridge LL59 5AB, UK
| | - E Abella
- Estación Biológica de Doñana, CSIC, C/ Américo Vespucio s/n, Sevilla 41092, Spain
| |
Collapse
|
4
|
Baptista M, Tapia G, Muñoz-Marmol A, Muncunill J, Montoto S, Gribben J, Calaminici M, Martinez A, Gonzalez-Farre B, López-Guillermo A, González-Barca E, Terol M, Miralles P, Alcoceba M, Vall-Llovera F, Briones J, Abrisqueta P, Abella E, Provencio M, García-Ballesteros C, Moraleda J, Sancho J, Ribera J, Mate J, Navarro J. APPLICATION OF CELL-OF-ORIGIN SUBTYPES DETERMINED BY DIGITAL GENE EXPRESSION IN HIV-RELATED DIFFUSE LARGE B-CELL LYMPHOMAS. Hematol Oncol 2017. [DOI: 10.1002/hon.2438_11] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- M. Baptista
- Department of Hematology; ICO-Hospital Universitari Germans Trias i Pujol, Josep Carreras Leukaemia Research Institute, Universitat Autònoma de Barcelona; Badalona Spain
| | - G. Tapia
- Department of Pathology; Hospital Universitari Germans Trias i Pujol, Universitat Autònoma de Barcelona; Badalona Spain
| | - A. Muñoz-Marmol
- Department of Pathology; Hospital Universitari Germans Trias i Pujol, Universitat Autònoma de Barcelona; Badalona Spain
| | - J. Muncunill
- Department of Hematology; ICO-Hospital Universitari Germans Trias i Pujol, Josep Carreras Leukaemia Research Institute, Universitat Autònoma de Barcelona; Badalona Spain
| | - S. Montoto
- Department of Haemato-Oncology, Barts Cancer Institute; Queen Mary University of London; London UK
| | - J. Gribben
- Department of Haemato-Oncology, Barts Cancer Institute; Queen Mary University of London; London UK
| | - M. Calaminici
- Department of Haemato-Oncology, Barts Cancer Institute; Queen Mary University of London; London UK
| | - A. Martinez
- Department of Pathology, Hospital Clinic, Institut d'Investigacions Biomediques August Pi I Sunyer (IDIBAPS); University of Barcelona; Barcelona Spain
| | - B. Gonzalez-Farre
- Department of Pathology, Hospital Clinic, Institut d'Investigacions Biomediques August Pi I Sunyer (IDIBAPS); University of Barcelona; Barcelona Spain
| | - A. López-Guillermo
- Department of Hematology, Hospital Clinic, Institut d'Investigacions Biomediques August Pi I Sunyer (IDIBAPS); University of Barcelona; Barcelona Spain
| | - E. González-Barca
- Department of Hematology; ICO-Hospital Duran i Reynals, L'Hospitalet de Llobregat; Spain
| | - M. Terol
- Department of Hematology and Oncology; Hospital Clínic Universitari de València; Valencia Spain
| | - P. Miralles
- Department of Infectious Diseases; Hospital Gregorio Marañón; Madrid Spain
| | - M. Alcoceba
- Department of Hematology; Hospital Universitario de Salamanca; Salamanca Spain
| | - F. Vall-Llovera
- Servicio de Hematología Clínica; Hospital Universitari Mutúa de Terrassa; Terrassa Spain
| | - J. Briones
- Department of Hematology, Hospital de la Santa Creu i Sant Pau; Josep Carreras Leukaemia Research Institute; Barcelona Spain
| | - P. Abrisqueta
- Department of Hematology; Hospital Vall d'Hebrón; Barcelona Spain
| | - E. Abella
- Department of Hematology; Hospital del Mar; Barcelona Spain
| | - M. Provencio
- Department of Medical Oncology; Hospital Universitario Puerta De Hierro; Majadahonda Spain
| | | | - J. Moraleda
- Department of Hematology; Hospital Clinico Universitario Virgen de la Arrixaca; Murcia Spain
| | - J. Sancho
- Department of Hematology; ICO-Hospital Universitari Germans Trias i Pujol, Josep Carreras Leukaemia Research Institute, Universitat Autònoma de Barcelona; Badalona Spain
| | - J. Ribera
- Department of Hematology; ICO-Hospital Universitari Germans Trias i Pujol, Josep Carreras Leukaemia Research Institute, Universitat Autònoma de Barcelona; Badalona Spain
| | - J. Mate
- Department of Pathology; Hospital Universitari Germans Trias i Pujol, Universitat Autònoma de Barcelona; Badalona Spain
| | - J. Navarro
- Department of Hematology; ICO-Hospital Universitari Germans Trias i Pujol, Josep Carreras Leukaemia Research Institute, Universitat Autònoma de Barcelona; Badalona Spain
| |
Collapse
|
5
|
Ferraro M, Gimeno E, Ble M, Subirana I, Gómez M, Díaz J, Sánchez-González B, García-Pallarols F, Martínez L, Belarte L, Abella E, Elosua R, Salar A. USEFULNESS OF N-TERMINAL BRAIN NATRIURETIC PEPTIDE LEVELS AND FRESCO SCALE FOR THE PREDICTION OF ANTHRACYCLINE-INDUCED CARDIOMYOTOXICITY IN PATIENTS WITH HODGKIN LYMPHOMA. Hematol Oncol 2017. [DOI: 10.1002/hon.2438_35] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- M. Ferraro
- Clinical Hematology, Research Group Applied in Hematological diseases; Autonomous University of Barcelona, Hospital del Mar, Institute of Medical Research of Hospital del Mar; Barcelona Spain
| | - E. Gimeno
- Clinical Hematology, Research Group Applied in Malalties Hematolgiques, Hospital del Mar; Institute of Medical Research of Hospital del Mar; Barcelona Spain
| | - M. Ble
- Cardiology; Hospital del Mar; Barcelona Spain
| | - I. Subirana
- CIBER of Epidemiology and Public Health, Research Group on Epidemiology and Cardiovascular Genetics, Hospital del Mar; Institute of Medical Research of Hospital del Mar; Barcelona Spain
| | - M. Gómez
- Cardiology; Hospital del Mar; Barcelona Spain
| | - J. Díaz
- Hematology; Autonomous University of Barcelona; Barcelona Spain
| | - B. Sánchez-González
- Clinical Hematology, Research Group Applied in Malalties Hematolgiques, Hospital del Mar; Institute of Medical Research of Hospital del Mar; Barcelona Spain
| | - F. García-Pallarols
- Clinical Hematology, Research Group Applied in Malalties Hematolgiques, Hospital del Mar; Institute of Medical Research of Hospital del Mar; Barcelona Spain
| | - L. Martínez
- Clinical Hematology; Hospital del Mar; Barcelona Spain
| | | | - E. Abella
- Clinical Hematology, Research Group Applied in Hematological diseases; Autonomous University of Barcelona, Hospital del Mar, Institute of Medical Research of Hospital del Mar; Barcelona Spain
| | - R. Elosua
- CIBER of Epidemiology and Public Health and Cardiovascular Diseases, Research Group on Epidemiology and Cardiovascular Genetics, Hospital del Mar; Institute of Medical Research of Hospital del Mar; Barcelona Spain
| | - A. Salar
- Clinical Hematology, Research Group Applied in Hematological diseases; Autonomous University of Barcelona, Hospital del Mar, Institute of Medical Research of Hospital del Mar; Barcelona Spain
| |
Collapse
|
6
|
Lyman GH, Dale DC, Legg JC, Abella E, Morrow PK, Whittaker S, Crawford JA. Abstract P3-15-08: A multicenter observational study to investigate the relationship between physician-assessed febrile neutropenia (FN) risk and prediction model FN or SN (severe neutropenia) risk in patients with breast cancer. Cancer Res 2013. [DOI: 10.1158/0008-5472.sabcs13-p3-15-08] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: A prediction model was previously developed to estimate the risk of SN or FN during the first cycle of chemotherapy, taking into account both the myelotoxicity of the chemotherapy regimen and the interplay of specific tumor and patient characteristics (Lyman, 2011). This model may potentially be useful for predicting which patients are at greatest risk for developing neutropenic complications, particularly among those patients receiving intermediate FN risk chemotherapy regimens, where the influence of patient characteristics becomes a critical consideration. To assess the clinical utility of this model, physicians assessed FN risk in patients with non-myeloid malignancies, and then physician-assessed FN risk was compared to prediction model risk.
Methods: This was a prospective, multicenter, observational study (124 community-based oncologists, 944 patients). Analysis of a breast cancer subgroup (93 oncologists, 364 patients) is reported here. Patients were eligible if they were: ≥18 years old, newly diagnosed, and candidates for initiating a new course of chemotherapy using an NCCN intermediate (10-20%) FN risk chemotherapy regimen. Oncologists entered clinical data about the patient into the model; they also made a clinical prediction of FN risk. Oncologists were blinded to both the data elements collected by the model and the risk predicted by the model. Data were only collected until the chemotherapy order was written; no outcome data were collected. The primary objective was to investigate the relationship between physician-assessed FN risk and prediction model SN or FN risk. As an exploratory endpoint, physicians were asked to estimate FN risk on the same set of four hypothetical case studies with varying FN risk factors. The correlation between risk probability scores was estimated as well as a 95% confidence interval accounting for intra-physician correlation. A smooth spline curve was fit to show the average relationship between physician-assessed and prediction model risk probability scores.
Results: Most patients were planning to receive TC (54%) and most had stage I-II disease (71%). Median (min, max) age was 58 years (23, 83). Physician-assessed FN risk correlated weakly with prediction model FN or SN risk: correlation 0.166 (95% CI: 0.027, 0.298). There was wide variability among all 124 physicians in their assessment of FN risk for the four case studies (Q1, Q3 case study 1: 20%, 40%; case study 2: 10%, 18%; case study 3: 20%, 40%; case study 4: 25%, 60%).
Conclusions: This study suggests that community oncologists would benefit from the use of an automated system for assessing FN risk among those receiving intermediate risk chemotherapy regimens. Such a system would help oncologists identify the patients who would benefit most from clinical intervention and help improve practice efficiency and quality of care.
Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P3-15-08.
Collapse
Affiliation(s)
- GH Lyman
- Duke University School of Medicine and The Duke Cancer Institute, Durham, NC; University of Washington, Seattle, WA; Amgen Inc., Thousand Oaks, CA
| | - DC Dale
- Duke University School of Medicine and The Duke Cancer Institute, Durham, NC; University of Washington, Seattle, WA; Amgen Inc., Thousand Oaks, CA
| | - JC Legg
- Duke University School of Medicine and The Duke Cancer Institute, Durham, NC; University of Washington, Seattle, WA; Amgen Inc., Thousand Oaks, CA
| | - E Abella
- Duke University School of Medicine and The Duke Cancer Institute, Durham, NC; University of Washington, Seattle, WA; Amgen Inc., Thousand Oaks, CA
| | - PK Morrow
- Duke University School of Medicine and The Duke Cancer Institute, Durham, NC; University of Washington, Seattle, WA; Amgen Inc., Thousand Oaks, CA
| | - S Whittaker
- Duke University School of Medicine and The Duke Cancer Institute, Durham, NC; University of Washington, Seattle, WA; Amgen Inc., Thousand Oaks, CA
| | - JA Crawford
- Duke University School of Medicine and The Duke Cancer Institute, Durham, NC; University of Washington, Seattle, WA; Amgen Inc., Thousand Oaks, CA
| |
Collapse
|
7
|
Marco A, Abella E, Liria-Loza A, Martins S, López O, Jiménez-Bordón S, Medina M, Oujo C, Gaona P, Godley BJ, López-Jurado LF. Abundance and exploitation of loggerhead turtles nesting in Boa Vista island, Cape Verde: the only substantial rookery in the eastern Atlantic. Anim Conserv 2012. [DOI: 10.1111/j.1469-1795.2012.00547.x] [Citation(s) in RCA: 52] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- A. Marco
- Estación Biológica de Doñana; CSIC; Seville; Spain
| | | | - A. Liria-Loza
- Instituto Canario de Ciencias Marinas; ICCM; Gran Canaria; Spain
| | - S. Martins
- Cabo Verde Natura 2000; Sal Rei; Boa Vista; Cape Verde
| | - O. López
- Instituto Canario de Ciencias Marinas; ICCM; Gran Canaria; Spain
| | | | - M. Medina
- Instituto Canario de Ciencias Marinas; ICCM; Gran Canaria; Spain
| | - C. Oujo
- Instituto Canario de Ciencias Marinas; ICCM; Gran Canaria; Spain
| | - P. Gaona
- Estación Biológica de Doñana; CSIC; Seville; Spain
| | - B. J. Godley
- Centre for Ecology & Conservation; University of Exeter; Penryn; Cornwall; UK
| | | |
Collapse
|
8
|
Bordoni RE, Haislip ST, Gilmore JW, Sharpe J, Abella E, Choi MR. P5-20-07: Estimation of Febrile Neutropenia in Women Receiving Docetaxel Plus Cyclophosphamide as Adjuvant Therapy for Early Stage Breast Cancer: A Retrospective Analysis. Cancer Res 2011. [DOI: 10.1158/0008-5472.sabcs11-p5-20-07] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: US Oncology Trial 9735 (Jones S, et al. JCO. 2006;24:5381–5387) established the docetaxel plus cyclophosphamide (TC) regimen as an effective adjuvant therapy for early stage breast cancer (ESBC). This trial did not specifically evaluate the incidence of febrile neutropenia (FN) as a study endpoint, but rates of 4%-8% were reported. Prophylactic granulocyte colony-stimulating factor (G-CSF) support was not allowed; reactive G-CSF support overall was not reported. Subsequent reports in the community setting have indicated FN rates of 25%-50% without G-CSF support and 0%-6.3% with G-CSF support (Table 1). To better determine the incidence of FN among ESBC patients treated with TC, we performed a retrospective clinical data review from the electronic medical record (EMR) database of Georgia Cancer Specialists, a large community oncology practice.
Methods: EMR data were captured between January 2006 and March 2010. Eligibility included women ≥ 18 years old with ESBC (stage I-IIIA) who completed ≥ 1 cycle of TC. The study time period was from the first dose of chemotherapy (CTX) to 6 weeks after the last dose of CTX, death, or loss to follow-up. The primary endpoint was the incidence of FN. Other endpoints included the incidence of severe (grade 3/4) neutropenia, neutropenia-related hospitalizations, G-CSF use, relative dose intensity (RDI), and dose delays and reductions. Results: Data from 662 patients were included in the analysis. Median age was 55 (range: 25–81) years. 40% of patients were white. The median number of CTX cycles received was 4 (range: 1–6). Most patients (91%) received G-CSF support; 73% as primary prophylaxis. See Table 2 for additional results.
Conclusions: This is the largest retrospective, community-based study to evaluate the incidence of FN in ESBC patients treated with TC. The observed FN rate of 5% (with 91% of patients receiving G-CSF) is consistent with other published reports using TC (Table 1). Our results suggest that TC is a taxane regimen with clinically significant myelosuppression (similar to other commonly used regimens in ESBC, such as TAC [NCCN Guidelines v2.2011]) and that the use of G-CSF support should always be considered.
Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr P5-20-07.
Collapse
Affiliation(s)
- RE Bordoni
- 1Georgia Cancer Specialists, Marietta, GA; Amgen Inc., Thousand Oaks, CA
| | - ST Haislip
- 1Georgia Cancer Specialists, Marietta, GA; Amgen Inc., Thousand Oaks, CA
| | - JW Gilmore
- 1Georgia Cancer Specialists, Marietta, GA; Amgen Inc., Thousand Oaks, CA
| | - J Sharpe
- 1Georgia Cancer Specialists, Marietta, GA; Amgen Inc., Thousand Oaks, CA
| | - E Abella
- 1Georgia Cancer Specialists, Marietta, GA; Amgen Inc., Thousand Oaks, CA
| | - MR Choi
- 1Georgia Cancer Specialists, Marietta, GA; Amgen Inc., Thousand Oaks, CA
| |
Collapse
|
9
|
Serrano D, Aguado J, Escola J, Peral A, Morales G, Abella E. Synthesis of hierarchical ZSM-5 by silanization and alkoxylation of protozeolitic units. Catal Today 2011. [DOI: 10.1016/j.cattod.2010.12.040] [Citation(s) in RCA: 55] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
10
|
Gimeno E, Sorli L, Abella E, Alvarez-Larran A, Horcajada JP, Garrigos L, Taus A, Salar A, Sanchez B, Pedro C, Besses C, Salvado M. Molecular diagnosis of bacteriemia in patients with neutropenic febrile oncohematologic. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.9033] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
11
|
Heras GL, Ribera JM, Roca-ribas F, Abella E, Batlle M, Roig I, Milla F. Primary Hodgkin's Disease of the Tonsil. Report of a Case and Review of the Literature. Leuk Lymphoma 2009. [DOI: 10.3109/10428199209064906] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|
12
|
Gallardo F, García-Muret MP, Servitje O, Estrach T, Bielsa I, Salar A, Abella E, Barranco C, Pujol RM. Cutaneous lymphomas showing prominent granulomatous component: clinicopathological features in a series of 16 cases. J Eur Acad Dermatol Venereol 2009; 23:639-47. [DOI: 10.1111/j.1468-3083.2008.03020.x] [Citation(s) in RCA: 46] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
13
|
Abella E, Gimenez T, Gimeno J, Cervera M, Pedro C, Gimeno E, Alvarez A, Salar A, Bellosillo B, Serrano S, Besses C. Diarrheic syndrome as a clinical sign of intestinal infiltration in progressive B-cell chronic lymphocytic leukemia. Leuk Res 2009; 33:159-61. [DOI: 10.1016/j.leukres.2008.03.023] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/29/2008] [Revised: 03/14/2008] [Accepted: 03/15/2008] [Indexed: 10/22/2022]
|
14
|
Sorli M, Gimeno E, Abella E, Besses C, Knobel H. Smoldering myeloma in HIV patient: A complete remission after antiretroviral therapy. Leuk Res 2008; 32:1482-3. [DOI: 10.1016/j.leukres.2007.11.022] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/15/2007] [Revised: 11/15/2007] [Accepted: 11/15/2007] [Indexed: 10/22/2022]
|
15
|
Peres E, Wood GW, Poulik J, Baynes R, Sood S, Abidi MH, Klein J, Bhambhani K, Dansey R, Abella E. High-dose chemotherapy and adoptive immunotherapy in the treatment of recurrent pediatric brain tumors. Neuropediatrics 2008; 39:151-6. [PMID: 18991194 DOI: 10.1055/s-0028-1093333] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
Abstract
Pediatric patients with recurrent brain tumors have a poor prognosis and limited therapeutic options. We investigated the use of high-dose chemotherapy with adoptive immunotherapy for recurrent brain tumors. Three pediatric patients with recurrent brain tumors received high-dose chemotherapy. This was followed by adoptive transfer of ex-vivo expanded T-cells. The T-cells were generated from peripheral blood after immunization with autologous cancer cells. The objectives of this study included (1) establishing the safety and feasibility of this potential treatment, (2) measuring changes in immune response after high-dose chemotherapy and adoptive immunotherapy, and (3) determining whether adoptive immunotherapy would be able to translate into a clinical response. Immune function was tested in all patients at the time of enrollment into the study. Humoral responses to recall antigens delayed-type hypersensitivity (DTH) were intact in all patients. After immunizing patients with autologous cancer cells, peripheral blood lymphocytes were harvested and activated with anti-CD3, expanded in-vitro, and infused post-autologous transplant. Patients received at least three doses of the vaccine, each consisting of an intradermal administration near a draining lymph node at biweekly intervals. Toxicity was limited and well tolerated in all patients. All three patients showed a tumor-specific immune response by serial imaging. Responses were durable at 16, 23, and 48 months, respectively.
Collapse
Affiliation(s)
- E Peres
- Dept. of Hematology & Oncology, Karmanos Cancer Institute, Div. of Pediatric Hematology-Oncology, and Dept. of Pediatric Neurosurgery, Children's Hospital of Michigan, Wayne State University School of Medicine, Detroit, Michigan, USA.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
16
|
Peres E, Savasan S, Klein J, Abidi M, Dansey R, Abella E. High fatality rate of Epstein-Barr virus-associated lymphoproliferative disorder occurring after bone marrow transplantation with rabbit antithymocyte globulin conditioning regimens. J Clin Microbiol 2005; 43:3540-3. [PMID: 16000501 PMCID: PMC1169101 DOI: 10.1128/jcm.43.7.3540-3543.2005] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022] Open
Abstract
Epstein-Barr virus (EBV)-associated lymphoproliferative disorder (EBV-LPD) following bone marrow transplantation can be fatal. The major risk factors for the development of EBV-LPD are ex vivo T-cell depletion or in vivo T-cell depletion with either antithymocyte globulin (ATG) or monoclonal anti-T-cell antibodies. Between March 1999 and January 2001, a total of 23 transplants with ATG of equine source (20 transplants) and ATG of rabbit source (3 transplants) used as part of the preparatory regimen were performed at the Barbara Ann Karmanos Cancer Institute in Detroit, Mich. The three patients who received rabbit ATG developed EBV-LPD between 60 and 90 days following bone marrow transplantation. However, there were no cases of EBV-LPD in the equine group. Treatment given in these cases consisted of tapering immunosuppression, antiviral therapy, unprocessed donor lymphocyte infusion, mobilized peripheral blood progenitor cell rescue infusion (one patient), and chemotherapy (one patient). All three patients died of complications from EBV-LPD. The association of rabbit ATG with the development of EBV-LPD suggests that patients receiving rabbit ATG as part of their preparatory regimens require close monitoring of the EBV viral load and possible early intervention with antiviral therapy.
Collapse
Affiliation(s)
- E Peres
- Bone Marrow Transplant Program, Barbara Ann Karmanos Cancer Institute, Harper Hospital of Michigan, 4100 John R, Detroit, MI 48201, USA.
| | | | | | | | | | | |
Collapse
|
17
|
Lamba R, Abella E, Kukuruga D, Klein J, Savasan S, Abidi MH, Mohamed A, Peres E. Mixed hematopoietic chimerism at day 90 following allogenic myeloablative stem cell transplantation is a predictor of relapse and survival. Leukemia 2004; 18:1681-6. [PMID: 15318247 DOI: 10.1038/sj.leu.2403468] [Citation(s) in RCA: 46] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
We retrospectively analyzed the prognostic significance of mixed chimerism and associated clinical parameters in 80 patients following unmanipulated allogenic stem cell transplantation. Chimerism studies were performed on marrow aspirates using fluorescent in situ hybridization and variable number tandem repeats techniques at day +30, day +90 and +12 months. The median overall survival (OS) was 24 months (range, 1-56 months). Mixed chimerism was found in 23, 28 and 14% of patients at day +30 (1 month), +90 (3 months), and +12 months, respectively. Day +30 chimerism studies failed to provide any prognostic information. Day +90 mixed chimeras (MC) had significantly higher relapse rates compared to day +90 complete chimeras (CC) at 6 months (P=0.03) and 18 months when compared to MC (P=0.03) following transplant. The median OS in day +90 MC and day+90 CC were, respectively (95% CI, 2-35 months), compared to 47 months (95% CI, 20-74 months) (P=0.02). In conclusion, chimerism studies on day +30 could be reserved for patients who fail to demonstrate engraftment. Day +90 MC had higher relapse rates and lower OS, and therefore may be considered for novel therapies and future studies.
Collapse
Affiliation(s)
- R Lamba
- Bone Marrow Transplant Program, Division of Bone Marrow Transplant, Barbara Ann Karmanos Cancer Institute, Wayne State University, Detroit, MI 48201, USA
| | | | | | | | | | | | | | | |
Collapse
|
18
|
Mellon-Reppen S, Dansey R, Abella E, Nehlsen-Cannarella S, Abidi M. Comparison of lymphoid and myeloid engraftment rates in patients receiving fludarabine/TBI or fludarabine/cyclophosphamide for non-myeloablative allogeneic transplantation. Biol Blood Marrow Transplant 2004. [DOI: 10.1016/j.bbmt.2003.12.251] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
19
|
|
20
|
Peres E, Madgie A, Abella E, Dansey R. 139EBV-associated lymphoproliferative disorder developing after conditioning with rabbit ATG. Biol Blood Marrow Transplant 2003. [DOI: 10.1016/s1083-8791(03)80140-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
21
|
Abella E, Feliu E, Granada I, Millá F, Oriol A, Ribera JM, Sánchez-Planell L, Berga LI, Reverter JC, Rozman C. Bone marrow changes in anorexia nervosa are correlated with the amount of weight loss and not with other clinical findings. Am J Clin Pathol 2002; 118:582-8. [PMID: 12375646 DOI: 10.1309/2y7x-ydxk-006b-xlt2] [Citation(s) in RCA: 119] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022] Open
Abstract
The clinical history and biochemical and hematologic variables for 44 consecutive patients diagnosed with anorexia nervosa were recorded. Bone marrow aspirates and biopsy specimens were analyzed by standard morphologic procedures, and bone marrow adipocytes were studied morphometrically. The bone marrow of the 44 patients was classified as normal (5 cases [11%]), hypoplastic or aplastic (17 [39%]), with partial or focal gelatinous degeneration (13 [30%]), or with complete gelatinous degeneration of the bone marrow (GDBM; 9 [20%]). These patterns correlated with amount of weight loss (P = .005) but not other clinical findings. WBC counts were lower in patients with GDBM (P = .0189), but this and other peripheral blood variables did not always reflect the severity of bone marrow damage. Hypoplastic or aplastic bone marrow showed an increase in bone marrow fat fraction due to an increase in adipocyte diameters, while in GDBM, fat fraction and adipocyte diameters decreased. Morphologic changes in bone marrow and stereologic alterations in bone marrow adipocytes may be observed in anorexia nervosa. The extent of damage is related to the amount of weight loss, not to other factors. Peripheral blood cell counts may not reflect the extent of damage. In some patients, this process may be reversible with reestablishment of adequate nutritional intake.
Collapse
Affiliation(s)
- E Abella
- Hematology Department, University Hospital Germans Trias i Pujol, Autonomous University of Barcelona, Badalona, Spain
| | | | | | | | | | | | | | | | | | | |
Collapse
|
22
|
Klein JL, Hamm C, Dansey RD, Karanes C, Abella E, Cassells L, Peters WP, Baynes RD. High-dose chemotherapy and CD34-selected peripheral blood progenitor cell transplantation for patients with breast cancer metastatic to bone and/or bone marrow. Bone Marrow Transplant 2001; 28:1023-9. [PMID: 11781611 DOI: 10.1038/sj.bmt.1703274] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/24/2001] [Accepted: 08/09/2001] [Indexed: 11/09/2022]
Abstract
Fifty women with breast cancer metastatic to bone or bone marrow involvement on light microscopy at the time of initial evaluation were treated with high-dose chemotherapy (HDC) and peripheral blood progenitor cell (PBPC) transplantation with CD34(+) cell selection using the Isolex 300i system. All patients received induction chemotherapy. PBPC were mobilized with chemotherapy and granulocyte colony-stimulating factor. The median CD34(+) progenitor purity was 94.7% (range 72-98.7%) and recovery 38.4% (range 21-60%). Forty-eight hours after HDC with cyclophosphamide, cisplatin and carmustine, PBPC were reinfused. Median time to neutrophil count >0.5 x 10(9)/l was 9 (range 9-12) days and to platelet transfusion independence 11 (4-30) days. These data demonstrate that selected CD34(+) PBPCs allow rapid hematologic reconstitution after HDC. During follow-up, 23% of patients developed herpes zoster. Two patients developed cytomegalovirus infections. Three patients developed fungal infections. The development of these infections was not associated with steroid use but appeared more frequently in patients with diabetes mellitus. Seventy-four per cent of patients received steroids for pulmonary toxicity. Treatment-related mortality was 4%. Progression-free survival and overall survival at 35 months was 22.4% and 40.5%, with a median of 11.4 months and 15.4 months, respectively.
Collapse
Affiliation(s)
- J L Klein
- Barbara Ann Karmanos Cancer Center, Wayne State University School of Medicine, Division of Hematology and Oncology, Detroit, MI, USA
| | | | | | | | | | | | | | | |
Collapse
|
23
|
Baynes RD, Dansey RD, Klein JL, Hamm C, Campbell M, Abella E, Peters WP. High-dose chemotherapy and hematopoietic stem cell transplantation for breast cancer: past or future? Semin Oncol 2001; 28:377-88. [PMID: 11498831 DOI: 10.1016/s0093-7754(01)90131-9] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Given that each year in the United States 180,000 new cases of breast cancer are diagnosed, with about 44,000 women succumbing to the disease, and that breast cancer is the second leading cause of cancer-related death in women, it is clear that existing therapy fails a large number of patients. Recently, a number of novel strategies have been developed in attempts to improve survival. These include agents used at very high dose requiring stem cell support. High-dose chemotherapy (HDC) with hematopoietic stem cell transplantation (HSCT), most frequently in the form of peripheral blood progenitor cell transplantation (PBPCT), is an highly active treatment approach in appropriate patients and the current data relating to this modality will be reviewed here. This article will attempt to place the recent randomized studies in perspective, to highlight the strengths and limitations of the data, and to offer some thoughts on future directions for the field.
Collapse
Affiliation(s)
- R D Baynes
- Bone Marrow Transplant Program, Barbara Ann Karmanos Cancer Institute, Department of Medicine, Wayne State University, Detroit, MI 48201, USA
| | | | | | | | | | | | | |
Collapse
|
24
|
Abstract
Acute myeloid leukemia (AML) has one of the lowest survival rates of childhood cancers. The first significant improvement in AML therapy started with the introduction of the now standard regimen of 3 days of anthracyclines and 7 days of cytarabine (Ara-C), the so-called 3+7 combinations. Several different therapeutic approaches have been taken in attempts to improve the outcome, including intensification of therapy both for remission induction and in the postremission phase. Intensification of postremission therapy included multiple courses of high-dose chemotherapy and/or myeloablative therapy followed by stem- cell rescue from either allogeneic or autologous sources. Furthermore, risk-tailored therapy is now possible, by cytogenetic risk stratification, promptness of remission induction, and identification of distinct clinical subgroups such as children with Down syndrome. This approach is rapidly changing potential therapeutic strategies for children with AML. It is in this changing mileu that we address the proper role of stem-cell transplantation, a modality that is changing (like chemotherapy) with expanding stem-cell sources and approaches to decrease transplant-related toxicity.
Collapse
Affiliation(s)
- E Abella
- Barbara Ann Karmanos Cancer Institute, Children's Hospital of Michigan, Wayne State University, 3901 Beaubien Boulevard, Detroit, MI 48201, USA.
| | | |
Collapse
|
25
|
Savaşan S, Abella E, Karanes C, Ravindranath Y. Recurrent breast relapses in a patient with acute lymphoblastic leukaemia following allogeneic bone marrow transplantation. Acta Haematol 2000; 99:95-7. [PMID: 9554458 DOI: 10.1159/000040819] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
Isolated extramedullary relapse is very rare after allogeneic bone marrow transplantation (BMT) in acute lymphoblastic leukaemia (ALL) and continues to be a therapeutic problem. We report recurrent breast relapses in a patient with ALL after allogeneic BMT. On both occasions, bone marrow cells were shown to be of donor origin and masses disappeared after systemic chemotherapy. Treatment of the isolated extramedullary relapse after allogeneic BMT is discussed.
Collapse
Affiliation(s)
- S Savaşan
- Barbara Ann Karmanos Cancer Institute, Children's Hospital of Michigan, Division of Hematology/Oncology, Detroit 48201, USA
| | | | | | | |
Collapse
|
26
|
Espinet B, Solé F, Lloveras E, Abella E, Besses C, Woessner S, Florensa L. Dicentric (17;18) in a case of atypical B-cell chronic lymphocytic leukemia. Cancer Genet Cytogenet 2000; 121:194-7. [PMID: 11063807 DOI: 10.1016/s0165-4608(00)00255-7] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
We report a new dic(17;18)(p11.2;p11.2) in a 61-year-old male patient diagnosed with atypical B-cell chronic lymphocytic leukemia. The dic(17;18)(p11.2;p11.2) was detected in 90%, 10%, and 100% of metaphases in the peripheral blood, bone marrow, and lymph node, respectively. Fluorescence in situ hybridization studies with chromosome 17 and 18 centromeric probes revealed the presence of two normal centromeres of both chromosomes 17 and 18. The centromere of one chromosome 17 was found together with the centromere of one chromosome 18, confirming the dicentric nature of the rearrangement. In addition, with the use of a 17p13.1 region probe, monosomy of the 17p13 region, where the Tp53 gene is located, was observed.
Collapse
Affiliation(s)
- B Espinet
- Laboratori de Citologia Hematològica/Laboratori de Referència de Catalunya, Unitat d'Hematologia 1973, Hospital del Mar, IMAS, IMIM, Barcelona, Spain
| | | | | | | | | | | | | |
Collapse
|
27
|
Lloveras E, Solé F, Espinet B, Besses C, Asensio A, Abella E, Woessner S, Florensa L. Cytogenetic and fluorescence in situ hybridization studies in four cases of plasma cell leukemia. Cancer Genet Cytogenet 2000; 121:163-6. [PMID: 11063801 DOI: 10.1016/s0165-4608(00)00243-0] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
We present a cytogenetic and fluorescence in situ hybridization (FISH) study, using centromeric probes for chromosomes 3, 7, 11, and 18, TP53 gene (17p13), and RB-1 locus (13q14) DNA probes, in four cases of plasma cell leukemia (PCL). Among the four cases, three presented monosomy of the RB-1 locus and one monoallelic deletion of the TP53 gene. The present report shows the usefulness of the FISH technique to detect abnormalities not previously observed by conventional cytogenetics.
Collapse
Affiliation(s)
- E Lloveras
- Laboratori de Citologia Hematològica/Laboratori de Referència de Catalunya, Unitat d'Hematologia, Hospital del Mar, Barcelona, Spain
| | | | | | | | | | | | | | | |
Collapse
|
28
|
Baynes RD, Hamm C, Dansey R, Klein J, Cassells L, Karanes C, Abella E, Peters WP. Bone marrow and peripheral blood hematopoietic stem cell transplantation: focus on autografting. Clin Chem 2000; 46:1239-51. [PMID: 10926918] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/17/2023]
Abstract
This review focuses on certain of the principles involved in high-dose chemotherapy and radiation therapy along with autologous hematopoietic stem cell transplantation for the treatment of certain malignancies. In addition, the evidence, wherever possible based on randomized data, for the application of this approach in certain malignancies is reviewed. The malignancies highlighted include acute myeloid leukemia, acute lymphoblastic leukemia, non-Hodgkin lymphoma, Hodgkin disease, and breast cancer.
Collapse
Affiliation(s)
- R D Baynes
- Bone Marrow Transplant Program, Barbara Ann Karmanos Cancer Institute at Wayne State University, 3990 John R, 4 Brush South, Detroit, MI 48201, USA.
| | | | | | | | | | | | | | | |
Collapse
|
29
|
Baynes RD, Dansey RD, Klein JL, Karanes C, Cassells L, Abella E, Wei WZ, Galy A, Du W, Wood G, Peters WP. High-dose chemotherapy and autologous stem cell transplantation for breast cancer. Cancer Invest 2000; 18:440-55. [PMID: 10834029 DOI: 10.3109/07357900009032816] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Affiliation(s)
- R D Baynes
- Bone Marrow Transplant Program, Barbara Ann Karmanos Cancer Institute, Wayne State University, Detroit, Michigan, USA
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
30
|
Espinet B, Solé F, Salido M, Lloveras E, Abella E, Besses C, Serrano S, Woessner S, Florensa L. Application of cross-species color banding (RxFISH) in the study of T-prolymphocytic leukemia. Haematologica 2000; 85:607-12. [PMID: 10870117] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/16/2023] Open
Abstract
BACKGROUND AND OBJECTIVE Cross-species color banding (RxFISH) is a new FISH technology based on the use of differentially labeled gibbon chromosome probes to obtain a specific color banding pattern for each human chromosome. The aim of the study was to test the RxFISH technique for better characterization of complex karyotypes in patients with T-prolymphocytic leukemia (T-PLL). DESIGN AND METHODS The study evaluated the cross-species color banding technique in four patients affected with T-PLL previously studied by conventional cytogenetics. RESULTS All patients showed an abnormal karyotype and three of them had a complex karyotype. The involvement of 14q11 in all four cases, the gain of 8q in three cases and a loss of chromosome 10, 15 and 17 and a gain of chromosome 21 in two cases were noted. The RxFISH technique identified from 2 to 7 not previously recognized aberrations per case and confirmed the inv(14)(q11q32). INTERPRETATION AND CONCLUSIONS To our knowledge, this is the first application of RxFISH to characterize chromosomal rearrangements in T-cell neoplasms. RxFISH gave rapid and easy identification of chromosome rearrangements that were difficult to recognize by conventional cytogenetics. Using this new technology we identified 15 rearrangements not detected by conventional cytogenetics.
Collapse
Affiliation(s)
- B Espinet
- Laboratori de Citologia Hematològica, Laboratori de Referència de Catalunya, Unitat d'Hematologia 1973, Barcelona, Spain.
| | | | | | | | | | | | | | | | | |
Collapse
|
31
|
Espinet B, Florensa L, Solé F, Lloveras E, Abella E, Besses C, Sans-Sabrafen J, Woessner S. Isochromosome +i(3)(q10) in a new case of persistent polyclonal B-cell lymphocytosis (PPBL). Eur J Haematol 2000; 64:344-6. [PMID: 10863981 DOI: 10.1034/j.1600-0609.2000.9l053.x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
|
32
|
Klein JL, Rey PM, Dansey RD, Karanes C, Du W, Abella E, Cassells L, Hamm C, Peters WP, Baynes RD. Cardiac sequelae of doxorubicin and paclitaxel as induction chemotherapy prior to high-dose chemotherapy and peripheral blood progenitor cell transplantation in women with high-risk primary or metastatic breast cancer. Bone Marrow Transplant 2000; 25:1047-52. [PMID: 10828864 DOI: 10.1038/sj.bmt.1702394] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
Doxorubicin plus paclitaxel has been shown to be an active regimen for metastatic breast cancer and is now frequently used as adjuvant therapy for high-risk primary breast cancer. Initial studies reported a higher than expected rate of cardiac toxicity with this regimen. We studied 105 patients with either high-risk primary breast cancer or metastatic breast cancer who were treated with doxorubicin (60 mg/m2) and 3-h infusions of paclitaxel (175 mg/m2) cycled every 3 weeks. Patients received three cycles of chemotherapy for high-risk primary or four cycles for metastatic disease. Patients then proceeded to high-dose chemotherapy (HDC) (STAMP I cyclophosphamide, cisplatin and carmustine) and peripheral blood progenitor cell transplantation (PBPCT). Patients underwent radionuclide multi-gated angiograms (MUGA) before and following induction chemotherapy and following HDC. During induction chemotherapy 40 (38%) of the patients had a reduction in left ventricular ejection fraction (LVEF). Fourteen had a decrease of 20% or greater and two were mildly symptomatic from CHF. There was additional reduction in the LVEF after HDC with a median value for LVEF of 59% (range, 20-78%). During HDC 10 patients developed clinical signs of congestive heart failure (CHF). Five patients responded to diuretic therapy and did not require any additional treatment. Four patients responded to vasodilation and/or digoxin with improvement in cardiac function. A clinically significant decrease in cardiac function was found in a small number of patients after induction chemotherapy and HDC with PBPCT. The majority of the patients tolerated this regimen without problems. Although there was a decline in LVEF as measured by radionuclide MUGA this did not prevent the majority of patients from proceeding with HDC. Bone Marrow Transplantation (2000).
Collapse
Affiliation(s)
- J L Klein
- Barbara Ann Karmanos Cancer Center, Wayne State University School of Medicine, Division of Hematology and Oncology, Detroit, Michigan, USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|
33
|
Espinosa-Parrilla Y, Navarro G, Morell M, Abella E, Estivill X, Sala N. Homozygosity for the protein S Heerlen allele is associated with type I PS deficiency in a thrombophilic pedigree with multiple risk factors. Thromb Haemost 2000; 83:102-6. [PMID: 10669162] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/15/2023]
Abstract
The multifactorial character of thrombotic disease is shown in a Spanish pedigree in which the propositus, with recurrent deep vein thrombosis, inherited the factor V R/Q506 mutation, the prothrombin 20210G/A variant and type III Protein S deficiency. Among 14 relatives carrying one or two of these three risk factors, thrombosis is present in a heterozygote for R/Q506 and in another for 20210G/A, who also had slightly positive antiphospholipid antibodies. Type I PS deficiency was also found in a young asymptomatic woman. PROS1 analysis showed coexistence of type III and type I PS deficiency to be associated with heterozygosity and homozygosity, respectively, for the P460 or PS Heerlen allele of the S/P460 variant. Analysis of PS values in this and other pedigrees segregating this variant revealed that not only free but also mean total PS levels are slightly but significantly lower in the SP460 heterozygotes than in the SS460 homozygotes. These findings strongly suggest a role of the P460 variant in the expression of the PS deficient phenotype.
Collapse
Affiliation(s)
- Y Espinosa-Parrilla
- Centre de Genètica Mèdica i Molecular, Institut de Recerca Oncològica, Barcelona, Spain
| | | | | | | | | | | |
Collapse
|
34
|
Klein J, Rey P, Dansey R, Karanes C, Abella E, Cassells L, Hamm C, Flowers M, Couwlier C, Peters W, Baynes R. Cyclophosphamide and paclitaxel as initial or salvage regimen for the mobilization of peripheral blood progenitor cells. Bone Marrow Transplant 1999; 24:959-63. [PMID: 10556954 DOI: 10.1038/sj.bmt.1702009] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
Peripheral blood progenitor cells are now commonly used for hematologic reconstitution after myelosuppressive chemotherapy for hematologic and solid malignancies. The purpose of this study was to evaluate the activity of paclitaxel 170 mg/m2 and cyclophosphamide 2 g/m2 (CP) with filgrastim (human G-CSF) for mobilization of PBPCs as the first or second maneuver after failure with filgrastim alone. Sixty-four patients with stage II-IV breast cancer received (CP) followed by filgrastim (10 microg/kg/day). In 35 (55%) this was the first maneuver while it was for salvage in 29 (45%) patients. The median number of aphereses was two (range, 1-7). In 83% of the patients apheresis was initiated on days 10-11 following chemotherapy. The median numbers of CD34+ cells/kg, CD34+ cells/apheresis/kg and total nucleated cells/kg collected were 8.7 x 10(6) (2.11-73.5), 3.97 x 10(6) (0.3-36.75) and 164.15 x 10(8) (9-660), respectively. All the patients yielded at least 2 x 10(6) CD34+ cells/kg. CP mobilization salvaged the 29 patients who failed mobilization with filgrastim alone. When used as first-line mobilization the yield of CD34+ cells x 10(6)/kg was higher than in the salvage group (16.93 vs 3.94, P < 0.001). Patients receiving CP as salvage reached the target of 5 x 10(6) CD34+ cells/kg in only 45% (13/29) of cases vs 94.3% as first maneuver. CP followed by filgrastim is a safe and effective regimen for the mobilization of PBPCs in patients with breast cancer and shows significant activity in patients who failed to mobilize with filgrastim, suggesting a higher mobilization potential.
Collapse
Affiliation(s)
- J Klein
- Bone Marrow Transplantation, Division of Hematology and Oncology, Barbara Ann Karmanos Cancer Institute, and Wayne State University, Detroit, MI 48201, USA
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
35
|
Affiliation(s)
- S Z Nadvi
- Division of Hematology/Oncology, Children's Hospital of Michigan, Detroit 48201, USA
| | | | | | | |
Collapse
|
36
|
Savaşan S, Lorenzana A, Williams JA, Mohamed AN, Ravindranath Y, Zielenska M, Hamre M, Haas JE, Rector F, Sawaf H, Abella E. Constitutional balanced translocations in alveolar rhabdomyosarcoma. Cancer Genet Cytogenet 1998; 105:50-4. [PMID: 9689930 DOI: 10.1016/s0165-4608(98)00014-4] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Abstract
Chromosomal analysis of tumor tissue from two children with alveolar rhabdomyosarcoma revealed t(1;5)(q32;q31) and t(1;22)(q21;q11.2) in all metaphases examined, respectively. Peripheral blood lymphocytes carried the same cytogenetic abnormality as that of the tumor cells in both patients. Parental lymphocytes were karyotypically normal in the patient with t(1;22), indicating a de novo constitutional translocation, but t(1;5) was paternally inherited in the other patient. The presence of constitutional translocations in these two children might have contributed to the development of alveolar rhabdomyosarcoma.
Collapse
Affiliation(s)
- S Savaşan
- Department of Pathology and Laboratory Medicine, Barbara Ann Karmanos Cancer Institute and Children's Hospital of Michigan, Detroit, USA
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
37
|
Savaşan S, Abella E, Akhtar AJ, Ravindranath Y. G-CSF treatment in acute leukemia. Leukemia 1997; 11:2210-1. [PMID: 9447843 DOI: 10.1038/sj.leu.2400857] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
|
38
|
|
39
|
Lundstrom TS, Fairfax MR, Dugan MC, Vazquez JA, Chandrasekar PH, Abella E, Kasten-Sportes C. Phialophora verrucosa infection in a BMT patient. Bone Marrow Transplant 1997; 20:789-91. [PMID: 9384484 DOI: 10.1038/sj.bmt.1700969] [Citation(s) in RCA: 22] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
Phialophora is a dematiaceous fungus isolated from soil and wood. Human infections including chromoblastomycosis, mycotic keratitis, cutaneous infections, and prosthetic valve endocarditis have been reported. We report a case of fatal hemorrhage due to Phialophora verrucosa in a patient with prolonged neutropenia undergoing autologous bone marrow transplant (BMT) for acute myelogenous leukemia (AML). Bacterial infections complicated induction and consolidation chemotherapies. Liposomal amphotericin B (LAMB) was given from day +33 to day +72 for febrile neutropenia. Death occurred on day +74 due to tracheal hemorrhage. Autopsy revealed granulation tissue on the posterior wall of the trachea with fungal hyphae on histopathology; the tissue grew Phialophora verrucosa. In vitro susceptibility studies revealed a minimum inhibitory concentration to AmB of 0.1 microg/ml. This represents the first reported case of invasive P. verrucosa in a BMT patient leading to fatal hemorrhage, despite large cumulative doses of LAMB to which the organism remained susceptible.
Collapse
Affiliation(s)
- T S Lundstrom
- Detroit Medical Center, Wayne State University, MI 48201, USA
| | | | | | | | | | | | | |
Collapse
|
40
|
Varterasian M, Janakiraman N, Karanes C, Abella E, Uberti J, Dragovic J, Raman SB, al-Katib A, Du W, Silver SM, Adams PT, Sensenbrenner L, Ratanatharathorn V. Transplantation in patients with multiple myeloma: a multicenter comparative analysis of peripheral blood stem cell and allogeneic transplant. Am J Clin Oncol 1997; 20:462-6. [PMID: 9345328 DOI: 10.1097/00000421-199710000-00005] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
We performed a multicenter comparative analysis of autologous peripheral blood stem cell transplantation (PBSCT) and allogeneic bone marrow transplantation (alloBMT) in multiple myeloma. Forty-eight consecutive patients received either PBSCT (24 patients) or alloBMT (24 patients) at one of three institutions in the study group. Preparatory regimens consisted of melphalan and total body irradiation (TBI) or melphalan alone in the PBSCT group. The alloBMT group received one of four regimens: cyclophosphamide and TBI; cyclophosphamide, VP-16 and 1,3-bis(2-chloroethyl)-1-nitrosourea (CVB); busulfan and cyclophosphamide (BU/CY) and total marrow irradiation (TMI); or melphalan and TBI. Procedure-related mortality was 12.5% for the PBSCT group and 25% for the alloBMT group. With a median follow-up for survivors in the PBSCT and alloBMT groups of 11 months (range, 4-46) and 15 months (range, 2-84 months), respectively, there was no significant difference in median overall survival (33.5 versus 38.6 months, p = 0.7637) or event-free survival (16.7 versus 31 months, p = 0.8450). There was, however, a plateau in survival at 40% in the alloBMT group. No plateau in survival was seen in the PBSCT group. Clinical relapses occurred as late as 39 months posttransplant. Patients have survived up to 28 months postrelapse.
Collapse
|
41
|
Ayala S, Colomer D, Aymerich M, Abella E, Vives Corrons JL. First description of a frameshift mutation in the alpha1-globin gene associated with alpha-thalassaemia. Br J Haematol 1997; 98:47-50. [PMID: 9233562 DOI: 10.1046/j.1365-2141.1997.1822999.x] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
A frameshift mutation in the alpha1-globin gene, responsible for a clinically mild alpha-thalassaemia phenotype, has been characterized in a Spanish woman. After excluding the most common forms of alpha-thalassaemia found in the Mediterranean area, both alpha-globin genes (alpha1 and alpha2) were amplified and analysed selectively by non-radioactive single-strand conformation polymorphism (SSCP). An abnormal SSCP mobility was present in the second exon of the alpha1-globin gene and direct sequence analysis revealed a 13 bp deletion (between codons 51 and 55) affecting a single allele. The consequence of this mutation is a reading frameshift leading to a novel amino acid coding sequence from codons 51-61 and a premature stop signal at new position 62, which results in a net reduction of the affected alpha-globin chain output. The presence of this new mutation was confirmed by restriction enzyme analysis of the specific PCR product.
Collapse
Affiliation(s)
- S Ayala
- Haematology Laboratory Department, Hospital Clínic i Provincial, University of Barcelona, Spain
| | | | | | | | | |
Collapse
|
42
|
Tolaymat A, Sandoval S, Abella E, Rawlings DJ. Clinical quiz. An infant with renal unresponsiveness. Pediatr Nephrol 1997; 11:121-3. [PMID: 9035185] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Affiliation(s)
- A Tolaymat
- University of Florida, College of Medicine, Department of Pediatrics, Jacksonville 32207, USA
| | | | | | | |
Collapse
|
43
|
|
44
|
Salinas R, Asensio A, Tuset E, Abella E, Bosch A, Las Heras G, Escoda L, Farré V, García M, García M, Jiménez C, Kian C, Martín E, Oriol A, Orriols J, Panadés M, Pero A, Prat M, Ramón O, Revilla E, Segalés JM, Vallés A. [Organizational models for the hematology areas of the district hospitals of Catalonia]. Sangre (Barc) 1996; 41:211-20. [PMID: 8755209] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
PURPOSE The haematological assistance in Catalonia is based upon the district hospitals, in the first step, and the stage III hospitals located usually in higher population nuclei, in the second step. The purpose of this work was to analyse the resources of the "primary haematological assistance" network provided by the district hospitals, to evaluate them and to propose a model for their organisation. MATERIAL AND METHODS An enquiry was carried out to all members of the Grup de Treball d'Hospitals Comarcals de Catalunya (Catalonia's District Hospitals Task Force). The evaluable data included demographic figures of the population assisted, personnel of each haematological area, organising structure, clinical activity, cytomorphology, blood banks, laboratories and continuous formation activities. RESULTS The enquiry was answered by 15 of the 21 district hospitals (71.4%) with haematologists in Catalonia. The population assisted in those hospitals is 2,100,000 (ranging between 55,000 an 450,000). All centres are integrated in the National Health network. Eleven of the hospitals analysed have only one haematologist (73.3%). If his dedication is 100% of the time, this would represent a doctor for 105,000 people. The time devoted to work is 690 hours a week for all the population, with a mean of 3,043. Four patients assisted per hour. The total number of hospital beds is 3,353 (50-450), with a mean number of 1 haematologist for every 167.6 beds. The number of patients hospitalized due to blood diseases ranges between 3 and 13 per month. Six of the 15 centres are adjunct to the outpatient clinic. Two centres have a blood bank and 7 have developed an autotransfusion programme. All the centres but one perform oral anticoagulant treatment follow-up, the number of patients assisted ranging from 20 to 210 per week. None of the hospitals has a separate Haematology Service; in most of them haematology is structurally and functionally dependent from Laboratories and in some there is a mixed Laboratory/Internal Medicine functional organisation, depending of the Medical Direction. No haematologist is ever on call specifically for his specialty. Continuous formation activities are carried out in 9 of the 15 centres (60%). COMMENT Several measures are proposed to improve the haematological assistance, acting on different levels: continuous formation, patient flows and circuits, resident doctors training, anticoagulant treatment network, organisation models, credit cards from the Spanish Association of Haematology.
Collapse
Affiliation(s)
- R Salinas
- Hospital General de Manresa, Barcelona
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
45
|
Shibuya TY, Momin F, Abella E, Jacobs JR, Karanes C, Ratanatharathorn V, Sensenbrenner LL, Lum LG. Sinus disease in the bone marrow transplant population: incidence, risk factors, and complications. Otolaryngol Head Neck Surg 1995; 113:705-11. [PMID: 7501381 DOI: 10.1016/s0194-5998(95)70009-9] [Citation(s) in RCA: 19] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Abstract
BACKGROUND Fever associated with sinus disease in the immunocompromised bone marrow transplant recipient requires prompt evaluation and therapy. Very little is known about the incidence, risk factors, and sequelae of nonsurgically treated sinus disease in this population. METHODS A retrospective review of 107 consecutive allogeneic and autologous bone marrow transplant recipients from August 1987 to July 1989 was performed to determine (1) the overall incidence of sinus disease; (2) factors that influence the development of sinus disease; and (3) the sequelae of sinus disease treated nonsurgically. RESULTS Overall 33 (31%) of 107 bone marrow transplant recipients had sinus disease defined as a radiographic abnormality with clinical symptoms. Eleven (10%) of 107 recipients had preexisting sinus disease. Sinus disease developed in 22 (21%) of 107 recipients after bone marrow transplantation. Sinus abnormalities were significantly higher among allografted bone marrow transplant recipients than among autografted recipients (p = 0.027). The diagnosis, stage of disease, cytoreductive regimen, or graft-vs.-host disease were not different between recipients in whom sinus disease did and did not develop. There were no deaths as a result of sinus complications. CONCLUSIONS Sinus disease developed in 21% of the studied population after bone marrow transplantation. Allogeneic recipients had a higher incidence of sinus disease than autologous recipients. There were no deaths attributed to sinus complications. All sinus disease in this bone marrow transplant population was treated medically. No patient required surgical intervention either before or after bone marrow transplantation.
Collapse
Affiliation(s)
- T Y Shibuya
- Department of Otolaryngology/Head and Neck Surgery, Detroit Medical Center Bone Marrow Transplantation Program, Michigan, USA
| | | | | | | | | | | | | | | |
Collapse
|
46
|
Varterasian M, Ratanatharathorn V, Uberti JP, Karanes C, Abella E, Momin F, Kasten-Sportes C, Al-Katib A, Lum L, Heilbrun LK. Clinical course and outcome of patients with Hodgkin's disease who progress after autologous transplantation. Leuk Lymphoma 1995; 20:59-65. [PMID: 8750624 DOI: 10.3109/10428199509054754] [Citation(s) in RCA: 20] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
Twenty-six of fifty-eight patients undergoing autologous bone marrow transplantation (autoBMT) or peripheral stem cell transplantation (PSCT) for Hodgkin's disease had progression of lymphoma (Hodgkin's or non-Hodgkin's) during the course of their follow-up. The majority of progressions, 81% (21/26), occurred within the first year of transplant; 12% (3/26) occurred at three years or more. Three patients developed a non-Hodgkin's lymphoma; all B-cell tumors primarily involving the gastrointestinal tract. The majority of patients (23/26) received at least one therapy after progression and 65% (17/26) of patients received multiple therapies. One patient who received a second BMT is alive without evidence of disease at 49 months following the second autologous BMT. The median survival for the entire group is 11 months. Forty-six percent (12/26) of patients survived more than one year and twenty-three percent (6/26) survived more than two years after disease progression. Post-progression survival is significantly related to time to progression.
Collapse
Affiliation(s)
- M Varterasian
- Department of Medicine, Wayne State University/Detroit Medical Center, Michigan, USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|
47
|
Abstract
The authors present two cases of clinical brain death that failed to meet the criteria for whole brain death using Tc-99m HMPAO. Conventional anterior cerebral flow studies demonstrated no intracerebral perfusion. Anterior static images also failed to show cerebral activity. However, the lateral images clearly demonstrate cerebellar activity. These cases demonstrate the importance of Tc-99m HMPAO as the agent of choice in evaluating brain death and the necessity of lateral views to meet the criteria for whole brain death. Cerebellar perfusion challenges the present criteria for whole brain death. New criteria must re-evaluate the present technology.
Collapse
Affiliation(s)
- M Spieth
- Department of Radiology, University of California, Davis Medical Center, USA
| | | | | | | | | | | |
Collapse
|
48
|
Ribera JM, Abella E, Lloreta J. [Polycythemia and splenomegaly in a 51-year-old woman]. Med Clin (Barc) 1995; 105:191-6. [PMID: 7630233] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Affiliation(s)
- J M Ribera
- Servicio de Hematología, Hospital Universitari Germans Trias i Pujol, Badalona
| | | | | |
Collapse
|
49
|
Schultz KR, Fernandez CV, Israel DM, Magee F, Wensley D, Sargent MA, Abella E, Karanes C. Association of gastroesophageal reflux with obstructive lung disease in children after allogeneic bone marrow transplantation. Blood 1995; 85:3763-5. [PMID: 7780159] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023] Open
|
50
|
Turkeri LN, Lum LG, Uberti JP, Abella E, Momin F, Karanes C, Sensenbrenner LL, Haas GP. Prevention of hemorrhagic cystitis following allogeneic bone marrow transplant preparative regimens with cyclophosphamide and busulfan: role of continuous bladder irrigation. J Urol 1995; 153:637-40. [PMID: 7861502 DOI: 10.1097/00005392-199503000-00022] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
High dose cyclophosphamide and/or busulfan conditioning treatment of recipients of bone marrow transplants proved to be highly effective but associated with substantial and sometimes life threatening hemorrhagic cystitis. To prevent this complication, a prophylactic continuous bladder irrigation program was instituted in patients receiving cyclophosphamide and/or busulfan in preparation for bone marrow transplantation. Retrospective analysis of 199 patients who underwent allogeneic bone marrow transplantation revealed that continuous bladder irrigation significantly decreased the frequency of hemorrhagic cystitis in patients receiving busulfan and cyclophosphamide (continuous bladder irrigation 23% versus no bladder irrigation 53%, p < 0.004). There was no difference in the frequency of hemorrhagic cystitis between the different preparative regimens in patients who underwent continuous bladder irrigation. There was no relationship between the incidence of hemorrhagic cystitis and the severity of graft-versus-host disease or the time to engraftment. The duration of hemorrhagic cystitis and overall survival rates were similar in both groups, and there was no increase in complications related to catheterization. In general, continuous bladder irrigation was well tolerated, decreased the incidence of hemorrhagic cystitis and may be useful in bone marrow transplant patients.
Collapse
Affiliation(s)
- L N Turkeri
- Department of Urology, Wayne State University School of Medicine, Detroit, Michigan 48201
| | | | | | | | | | | | | | | |
Collapse
|